SVA fundamentals
An in-depth look to Sinovac Biotech, Ltd. operating, investing, and financing activities
SVA free cash flow for H2 23 is 94.41 M USD. For 2023, SVA free cash flow was -38.52 M USD and operating cash flow was 106.02 M USD.
0.00
Cash from operating activities
Cash from investing activities
Cash from financing activities
Currency: USD
TTM